Acadia Healthcare Company, Inc. (ACHC) Stock Price & How to Invest

Acadia Healthcare (NASDAQ: ACHC) is the leading pure-play behavioral healthcare provider in the United States, operating roughly 277 facilities with more than 12,500 licensed beds across about 40 states and Puerto Rico as of the end of 2025. Its business spans four service lines: acute inpatient psychiatric hospitals (its largest and fastest-growing segment), specialty treatment facilities, comprehensive treatment centers for opioid-use disorder, and residential treatment centers. Revenue is heavily tied to government payors, with Medicaid at roughly 58 percent, commercial at about 25 percent, and Medicare near 14 percent, and no single facility contributing more than about 4 percent of total revenue.

The investment picture combines a genuinely strong demand backdrop for mental-health and addiction services with a growth model built on same-facility volume gains, higher revenue per patient day, and continued bed additions through de novo hospitals and joint ventures. Full-year 2025 revenue reached about $3.31 billion, up roughly 5 percent, and 2026 guidance given in the spring pointed to $3.37 billion to $3.45 billion. Trailing revenue through June 2026 was about $3.37 billion, and the second quarter brought ~$866 million of revenue with adjusted EPS of ~$0.38, ahead of a ~$0.35 consensus, the fourth straight quarter above estimates. Offsetting this are material risks: elevated patient-related litigation costs, a DOJ criminal subpoena tied to admissions and billing practices, a settled securities class action, and a leveraged balance sheet, all of which have kept the stock volatile and well below prior highs. The shares have rebounded hard in 2026: at ~$30.52 on October 16 they were up ~114% year to date and ~23% over one year, though down ~14% over the past three months from a 52-week high near $35.83.

Legal and regulatory exposure is the defining risk. Acadia agreed to pay $179 million to settle a securities class action tied to prior disclosures, faces a September 2024 DOJ Criminal Division grand jury subpoena related to its acute admissions, length of stay, and billing practices, and disclosed a sharp rise in patient-related litigation expense (roughly $116 million projected for 2025 versus $54 million in 2024). A 2024 New York Times investigation alleged patients were improperly detained, and a May 2026 California jury awarded $105 million in a retaliatory-termination case. The company also carries meaningful leverage, with total debt around $2.6 billion against ~$171 million of cash at June 30, 2026, and took a large goodwill impairment in late 2025 that left trailing twelve-month net income at about -$1.1 billion. Free cash flow over the trailing year was negative (about -$105 million) as capital spending on new beds outran operating cash flow of ~$211 million. Heavy Medicaid and Medicare reliance leaves it exposed to reimbursement-rate and policy changes.

14 analysts publish price targets on ACHC, averaging $33.79 against a $29.98 price as of October 2026, or +12.7%. The published targets run from $17.00 to $41.00, a wide spread, and the ratings split 8 buy, 5 hold, 1 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ACHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Acadia Healthcare Company, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Structural demand for behavioral health. Mental-health and substance-use treatment remains chronically undersupplied in the US, giving Acadia a long runway of demand across its acute, residential, and addiction service lines. The most optimistic published target, $41.00, assumes this works close to its best case.

The case against. Legal and regulatory exposure is the defining risk. The most pessimistic target, $17.00, is roughly what ACHC is worth if this bites instead.

Read the full bull and bear case on ACHC, including what would have to change to break either one. Walnut is not an investment adviser.

No. Acadia Healthcare Company, Inc. (ACHC) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Acadia Healthcare Company, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.37B (Q2 2026 ~$866M)
• 2026 revenue guidance (spring): ~$3.37B to $3.45B
• Q2 2026 adj. EPS: ~$0.38 (vs ~$0.35 est.)
• Net income (TTM): ~-$1.13B (late-2025 impairment)
• Forward P/E: ~16.5x
• EV / EBITDA: ~10.3x
• Market cap: ~$2.8B

Acadia closed at ~$30.52 on October 16, 2026, up ~114% year to date after the stock rebounded from a 52-week low near $11.43. It trades at about 16.5x forward EPS and ~10.3x EV/EBITDA, with analysts' mean target near $33.79 across 14 firms, so the market is still discounting legal and reimbursement uncertainty. Reported earnings remain depressed by the late-2025 impairment, legal and interest costs even as adjusted metrics grow.

Other names that sit close to ACHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ACHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ACHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ACHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Acadia is a category-leading behavioral health operator with durable demand and a growing bed base, but its investment case hinges on how the ongoing legal, DOJ, and patient-litigation issues play out against its leverage. After more than doubling in 2026 to ~$30.52, the stock trades around 16.5x 2027 consensus EPS, so the November 4 report and any legal news carry weight.

Whether ACHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ACHC a buy or a sell?, and where the stock could go from here in the ACHC stock forecast.

For income investors, whether ACHC pays a dividend and how the payout looks is covered in does ACHC pay a dividend? And to weigh ACHC against a peer, read the full side-by-side comparisons: ACHC vs UHS and ACHC vs HCA.